Coya Therapeutics completes enrollment in ALSTARS ALS trial
Coya Therapeutics has completed enrollment of the planned 120 participants in the Phase 2/3 ALSTARS trial evaluating COYA 302 for amyotrophic lateral sclerosis. Additional eligible participants already in active screening will be allowed to enroll. Topline data from the 24-week double-blind treatmen
<p>Coya Therapeutics has completed enrollment of the planned 120 participants in the Phase 2/3 ALSTARS trial evaluating COYA 302 for amyotrophic lateral sclerosis. Additional eligible participants already in active screening will be allowed to enroll. Topline data from the 24-week double-blind treatmen</p>